Fraction of Cancer Attributable to Carcinogenic Drugs in Korea from 2015 to 2030.

Sangjun Lee, Kwang-Pil Ko, Jung Eun Lee, Inah Kim, Sue K Park, Sungji Moon, Soseul Sung, Youjin Hong, Kyungsik Kim, Woojin Lim

Journal: Cancer research and treatment 2025;57(3):635-648

PMID: 39512062

Abstract

PURPOSE

This study aims to estimate and project the population attributable fraction (PAF) of cancer incidence and death due to carcinogenic drug use in Korea from 2015 to 2030, to estimate the degree of cancer prevention from exposure to carcinogenic drugs in Korea. Selected carcinogenic drugs were immunosuppressive and antineoplastic drugs classified as group I by the International Agency for Research on Cancer.

MATERIALS AND METHODS

Systematic review and meta-analyses were conducted to estimate the relative risk of cancer associated with carcinogenic drug use. Age was standardized using the annual prevalence rate of the National Health Insurance Service sample cohort (NHIS-NSC) from 2002 to 2013 to calculate the standardized prevalence rate of carcinogenic drug use each year. The PAF of specific cancer incidence and death were calculated using Levin's formula and Monte Carlo methods. The prevalence rates were extrapolated to estimate the trend of PAF from 2015 to 2030.

RESULTS

In 2015, carcinogenic drugs attributed to 0.003% and 0.002% among the causes of cancer incidence and death in Korea. However, carcinogenic drugs attributed to 1.1% among the causes of both cancer incidence and death in patients with clinical indications of carcinogenic drugs.

CONCLUSION

The PAF in patients with clinical indications of carcinogenic drugs were significantly high and expected to increase rapidly over time. Since these drugs are listed as essential by the World Health Organization, and may be difficult to replace, a surveillance system on susceptible populations using group I carcinogenic drugs must be discussed and implemented.

Address: Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea.; Cancer Research Institute, Seoul National University, Seoul, Korea.; Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea.; Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea.; Cancer Research Institute, Seoul National University, Seoul, Korea.; Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Korea.; Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea.; Cancer Research Institute, Seoul National University, Seoul, Korea.; Interdisciplinary Program in Cancer Biology, Seoul National University College of Medicine, Seoul, Korea.; Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea.; Cancer Research Institute, Seoul National University, Seoul, Korea.; Department of Food and Nutrition, Seoul National University College of Human Ecology, Seoul, Korea.; Department of Occupational and Environmental Medicine, Hanyang University College of Medicine, Seoul, Korea.; Clinical Preventive Medicine Center, Seoul National University Bundang Hospital, Seongnam, Korea.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.